CDC42 and breast cancer: To explore whether oncogenic alterations in Rho/Rac1/CDC42 signaling are further enriched in metastatic vs primary breast cancer, we compared the rate of missense mutations and copy number alterations (CNA) in 42 genes associated with these pathways (listed in Supplemental Fig. S10a).